

High-risk human papillomavirus infections in breast cancer in Syrian women and their association with Id-1 expression: a tissue microarray study

N Akil^{1,4}, A Yasmeen^{2,4}, A Kassab², L Ghabreau¹, AD Darnel^{2,3} and A-E Al Moustafa^{*,1,2,3}

¹Faculty of Medicine, University of Aleppo, Aleppo, Syria; ²Segal Cancer Centre, Lady Davis Institute for Medical Research of the Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada; ³Program in Cancer Genetics, Department of Oncology, McGill University, Montreal, Quebec, Canada

High-risk human papillomaviruses (HPVs) could be important risk factors for breast carcinogenesis and metastasis. Based on this hypothesis, we recently studied the effect of E6/E7 onco-proteins of high-risk HPV type 16 in two non-invasive human breast cancer cell lines, BT20 and MCF7; we reported that E6/E7 converts these cell lines to invasive cells. This is accompanied by an overexpression of Id-1, which is an important regulator of breast metastasis. In this investigation, we examined the presence of high-risk HPVs (16, 18, 31, 33 and 35) and the expression of their E6 onco-protein as well as their correlation with Id-1 gene expression, using polymerase chain reaction (PCR) and tissue microarray (TMA) analysis, respectively, in a cohort of 113 Syrian breast cancer patients. We found that high-risk HPV types 16, 18, 31, 33 and 35 are present in 8.84, 9.73, 7.07, 55.75 and 37.16% of our samples, respectively, which represent invasive breast cancers. Overall, 69 (61.06%) of the 113 samples are HPV positive; among these specimens 24 tissues (34.78%) are coinfecting with more than one HPV type. Furthermore, we report that the expression of the E6 onco-protein of these high-risk HPVs is correlated with Id-1 overexpression in the majority of invasive breast cancer tissue samples. Our data suggest that high-risk HPV infections are associated with human breast cancer progression in Syrian women.

British Journal of Cancer (2008) **99**, 404–407. doi:10.1038/sj.bjc.6604503 www.bjcancer.com

Published online 22 July 2008

© 2008 Cancer Research UK

Keywords: breast cancer; high-risk HPV; Id-1 gene

High-risk human papillomaviruses (HPVs) are important risk factors for numerous human cancers including cervical, colorectal and head and neck (HN); as roughly 96, 80 and 28% of these cancers are positive for high-risk HPVs, respectively (Damin *et al*, 2007; Sturgis and Cinciripini, 2007; de Sanjosé *et al*, 2007). In addition, the presence of high-risk HPVs serve as prognostic factors in early-stage cervical, colorectal and HN cancers, and are associated with vascular invasion, lymph node metastases and tumour size (Begum *et al*, 2003; Graflund *et al*, 2004; Zuna *et al*, 2004; Umudum *et al*, 2005; Varnai *et al*, 2006). The E6 and E7 onco-proteins of high-risk HPVs, which are constitutively expressed in these cancers, inactivate p53 and pRb tumour suppressors, respectively (Vousden, 1995). E6 facilitates the degradation of p53 through its association with an accessory protein, E6-AP, a component of the ubiquitin proteolytic pathway (Scheffner *et al*, 1993). Although, E7 proteins of high-risk HPVs bind to Rb (Dyson *et al*, 1989), as well as to other pocket proteins, such as p107 and p130 (Dyson *et al*, 1992), leading to cell cycle

deregulation. This results in genomic instability and has been implicated in the progression of normal cells into cancer cells.

Several recent studies reported that approximately 50% of human breast cancers are positive for high-risk HPVs, especially types 16, 18 and 33 (Yu *et al*, 2000; Liu *et al*, 2001; de Villiers *et al*, 2005; Kan *et al*, 2005); controversially a few studies revealed that HPVs could not be detected in breast cancer and normal tissues (Gopalkrishna *et al*, 1996; Lindel *et al*, 2007). On the other hand, studies that found HPV-positive samples revealed that certain types of high-risk HPV infections are linked to specific geographic locations. According to this observation, we recently reported that HPV type 16 is the only type of high-risk HPV present in breast cancer tissues of Canadian women (Yasmeen *et al*, 2007a).

The Id-1 gene (inhibitor of differentiation and DNA binding), a member of the helix-loop-helix transcription factor family, has multiple functions, including inhibition of differentiation, induction of proliferation and delaying replicative senescence (Fong *et al*, 2004; Sikder *et al*, 2003). Moreover, Id-1 has been suggested as a potential oncogene, because it is upregulated in many types of human cancer such as breast, prostate and cervical (Lin *et al*, 2000; Schindl *et al*, 2001; Ouyang *et al*, 2002). In breast cancer patients, enhanced Id-1 expression is correlated with more aggressive behaviour as well as much shorter overall survival (Schoppmann *et al*, 2003; Jang *et al*, 2006). These studies suggest that Id-1 plays a positive role in promoting the development and progression of human breast cancer.

*Correspondence: Professor A-E Al Moustafa, Segal Cancer Centre, Lady Davis Institute for Medical Research of the Sir Mortimer B Davis-Jewish General Hospital, 3755, Ch. de la Cote Ste-Catherine, Montréal, Québec, Canada H3T 1E2.

E-mails: ala-eddin.almoustafa@mcgill.ca or aalmoust@ldi.jgh.mcgill.ca

⁴These authors contributed equally to this work.

Received 28 March 2007; revised 31 May 2008; accepted 10 June 2008; published online 22 July 2008

This study aims to recognise the specific types of high-risk HPV infections present in Syrian women and their association with tumour aggressiveness and Id-1 overexpression.

MATERIALS AND METHODS

HPV detection and type specification

A total of 113 blocks from breast cancer patients with a median age of 52 (range, 26–66) years were used in this study. Formalin-fixed (buffered neutral aqueous 10% solution), paraffin-embedded tumour materials were obtained from the Department of Pathology, Faculty of Medicine, University of Aleppo. The use of these specimens and data in research was approved by the Ethics Committee of the Faculty of Medicine of Aleppo University. Five μ g of purified DNA (from each sample) was analysed for HPV by multiplex PCR targets to the conserved L1 region of the viral genome by use of PGMY09/11 L1 primer pools (Begum *et al*, 2003; Yasmeen *et al*, 2007a,b). In parallel, we used specific primers for E6 and E7 genes to detect HPV types 16, 18, 31, 33 and 35, whereas, specific primers for the GAPDH gene were used as an internal control (Table 1). PCR products were denatured in 0.13N NaOH and hybridised to an immobilised HPV probe array using an extended reverse line-blot assay for HPV genotyping (Roche Molecular Systems Inc., Alameda, CA, USA) of five HPV types classified as high-risk HPVs (types 16, 18, 31, 33 and 35) as described by Begum *et al* (2003).

Tissue microarray

The tissue microarray (TMA) construction was performed as described by Kuefer *et al* (2004). Briefly, tissue cylinders with a diameter of 0.6 mm were punched from representative tumour areas of a 'donor' tissue block using a semiautomatic robotic precision instrument. Two sections of the TMA blocks were transferred to an adhesive coated slide system (Instrumedics Inc.,

Hackensack, NJ, USA). Slides of the finished blocks were used for immunohistochemistry analysis.

Immunohistochemistry

Immunohistochemical procedures examining the expression of Id-1 and E6 were carried out using standard procedures as previously described (Al Moustafa *et al*, 2004). Primary specific antibodies were obtained from Santa Cruz Biotechnology and Calbiochem. Briefly, TMA sections were deparaffinised, rehydrated and endogenous peroxidase activity within the rehydrated tissue was blocked with a solution of 3% hydrogen peroxide in methanol for 10 min at room temperature. Antigen retrieval was carried out by boiling in 10 mM sodium citrate solution (pH 6.0) for 10 min. The TMA slides were cooled and equilibrated in Optimax™ wash buffer then incubated overnight (15 h) at 4°C with primary antibodies for Id-1 (rabbit polyclonal; sc-488; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and E6 (mouse monoclonal; clone C1P5; Calbiochem, San Diego, CA, USA). In all cases, the diluent was 0.6% BSA in Optimax wash buffer. Sections were then washed (4 × 1 min), and the appropriate secondary HRP-conjugated antibody was applied for 1 h at room temperature (Calbiochem, Canada). The slides were counterstained with haematoxylin and mounted.

RESULTS

To determine the role of high-risk HPV infections in human breast cancer in Middle Eastern women, we investigated the presence of high-risk HPV types 16, 18, 31, 33 and 35 in a cohort of 113 breast cancer samples from Syrian women by PCR analysis using specific primers for their E6 and/or E7 genes (Table 1). Our study revealed that 69 (61.06%) of the 113 samples are HPV positive and 24 (34.78%) of these specimens are coinfecting with more than one HPV type (Table 2). We found that HPV types 16, 18 and 31 are present in only 10, 11 and 8 cancer tissues, respectively (Table 3). In contrast, 63 and 42 cancer tissues were positive for HPV types 33 and 35, respectively (Table 3).

To assess the association between the presence of HPV types 16, 18, 31, 33 and 35 with tumour aggressiveness and Id-1 expression in breast cancer in Syrian women, we examined the expression of the E6 onco-protein of high-risk HPVs along with Id-1 expression

Table 1 The specific primer sets for E6 and/or E7 genes of high-risk HPVs used for PCR amplification

HPV types	Region	Primers
16	E6	5'-ATGCACCAAAAGAGAACTGCA-3' 5'-TTACAGCTGGGTTTCTCTACG-3'
16	E7	5'-ATGCATGGAGATACACCTACATTGCAT-3' 5'-GTTTCTGAGAACAGATGGGGCACAC-3'
18	E6	5'-GCTTTGAGGATCCAACACGG-3' 5'-TGCAGCACGAATGGCACTGG-3'
31	E7	5'-GGGCTCATTTGGAATCGTGTG-3' 5'-AACCATTGCATCCCGTCCCC-3'
33	E6	5'-TGTAACCGAAAGCGGTTCAA-3' 5'-TAACGTTGGCTTGTGCTCTC-3'
33	E7	5'-TGAGGATGAAGGCTTGACC-3' 5'-TGACACATAAACGAAGTGTG-3'
35	E6	5'-GGTCGTACCGAAACGGTTG-3' 5'-GTTGCCTCGGTTCCAAATC-3'
35	E7	5'-CTATTGACGGTCCAGCT-3' 5'-TACACACAGACGTAGTGTGCG-3'

Primers specific for the GAPDH gene, 5'-GAAGGC-CATGCCAGTGAGCT-3' and 5'-CCGGGAACTGTGGCGTGAT-3', were used as an internal control.

Table 2 High-risk HPV (16, 18, 31, 33 and 35) detection in breast carcinomas by PCR

	Tested cases	Positive	Percentage
Breast cancer tissues	113	69	61.06

The incidences of these viruses were found in 69 samples out of 113 examined using specific primers for E6 and/or E7 of each HPV type ($P < 0.01$). We noted that 24 samples of the 69 are infected with more than one HPV type ($P < 0.01$).

Table 3 Presence of HPV types 16, 18, 31, 33 and 35 in invasive and *in-situ* breast carcinomas

Breast cancer	No of cases	HPV types				
		16	18	31	33	35
Invasive	87	9/87	11/87	8/87	58/87	39/87
<i>In situ</i>	26	1/26	0/26	0/26	5/26	3/26

The presence of high-risk HPVs is more frequent in invasive breast cancer in comparison to *in situ* breast cancer tissues ($P < 0.0001$ and 0.024). Furthermore, it is clear that HPV type 33 and 35 are more common in breast cancer in Syrian women.

in all our breast tissue samples by immunohistochemistry using tissue microarray methodology. We found that E6 expression is correlated with Id-1 overexpression in 94.25% of invasive breast cancer samples as opposed to 30.76% of *in situ* cancer tissues (Table 4 and Figure 1); whereas we presume that these *in situ* breast carcinomas, which are HPV-positive, will ultimately progress into invasive carcinomas under the effect of these HPVs, as they are already intermediate to high nuclear grade. Moreover, to confirm the association between E6/E7 of HPV types 16, 18, 31, 33 and 35 and Id-1, we investigated the presence of E6 and/or E7 of these viruses by PCR using specific primers for E6/E7 genes (Table 1). By means of this analysis, we were able to prove that E6/E7 of HPV types 16, 18, 31, 33 and 35 are present in the majority of invasive breast cancer tissues; and their presence is associated with Id-1 overexpression (Table 4).

DISCUSSION

This is, to the best of our knowledge, the first study on the presence of high-risk HPVs and their relation with tumour aggressiveness in breast cancer in Syrian women. Earlier studies on breast cancer have reported that HPV types 11, 16 and 18 are the most frequent in women living in the United States and Brazil (Liu *et al*, 2001; Damin *et al*, 2004); and HPV type 18 is present in the majority of Australian women (Kan *et al*, 2005). In parallel, HPV type 33 is the most frequent virus in Asian women (Yu *et al*, 1999, 2000). HPV type 16 has been identified in Italian and Norwegian women who had previous cervical neoplasias (Hennig *et al*, 1999). Moreover, we recently reported that HPV type 16 is the only type present in Canadian women. However, studies on the presence of high-risk HPV in the Middle East reveal that HPV types 18, 33 and 35 are present in breast cancer and normal mammary tissues in Turkish women (Gumus *et al*, 2006). On the other hand, the presence of HPVs in human breast cancer tissues

varies from 12.9 to 86% (de Villiers *et al*, 2005; Tsai *et al*, 2005). In this study, we report that HPVs are present in 61.06% of breast cancer in Syrian women; moreover, HPV types 33 and 35 are the predominant viruses of the high-risk HPV family in these breast cancer tissues. Therefore, our data confirm that specific types of high-risk HPV infection, in breast tissues, are related to specific geographic locations.

Regarding the association between high-risk HPV and tumour aggressiveness, recent studies, including ours, have reported that the presence of HPV type 16, in human breast cancer, is correlated with invasive carcinomas (Kroupis *et al*, 2006; Yasmeen *et al*, 2007a). Moreover, we demonstrated that E6/E7 onco-proteins of HPV type 16 convert non-invasive breast cancer cells to an invasive phenotype (Yasmeen *et al*, 2007a); this is accompanied by an overexpression of Id-1, which regulates cell invasion and metastasis of human breast cancer cells (Desprez *et al*, 1998; Fong *et al*, 2003). In this study, we investigated the relation between high-risk HPVs and Id-1 expression in breast cancer tissues from Syrian women. We report, for the first time, that the presence of E6/E7 onco-proteins of HPV types 16, 18, 31, 33 and 35 are associated with Id-1 overexpression. Recently, Minn *et al* (2005) identified a subset of genes that mediate lung metastasis of human breast cancer; Id-1 was revealed as one of these important genes. We recently found that human breast cancer cells expressing E6/E7 of HPV type 16 display a major lung metastatic activity when compared with their wild type cells *in vivo*. Separately, we reported that the presence of E6/E7 of HPV type 16 is correlated with Id-1 overexpression in human invasive and metastatic breast cancer tissues in Canadian women. Moreover, we revealed that E6/E7 of HPV type 16 affects Id-1 deregulation through the activation of its promoter (Yasmeen *et al*, 2007a). Therefore, the present study clearly suggests that Id-1 is the downstream target of E6/E7 of HPV types 18, 31, 33 and 35 in human breast cancer progression.

In conclusion, we demonstrate that high-risk HPV types 16, 18, 31, 33 and 35 are present in human breast cancer in Syrian women. In addition, HPV types 33 and 35 are the most dominant types of HPV infection found in Middle Eastern women, based on the combination of this study and a study by Gumus *et al* (2006). In parallel, we report that Id-1 is an important target for E6/E7 onco-proteins of HPV type 16, 18, 31, 33 and 35 in breast cancer cells. Our findings provide a new basis for understanding the mechanisms of high-risk HPV infections and their relation to human breast cancers. However, we firmly believe that further studies are required to elucidate the role and pathogenesis of high-risk HPV in human breast cancer, especially because HPV vaccines for only two high-risk HPV types are available at present. Therefore, it is of great interest to gain a better understanding of the association between HPV infections and breast cancer progression.

Table 4 Correlation between the expression of the E6 onco-protein of high-risk HPVs and Id-1 in breast cancer tissues using tissue microarray analysis

Breast cancer	No of cases	E6 of HPV	Id-1
Invasive	87	82/87	84/87
<i>In situ</i>	26	11/26	8/26

The expression of the E6 onco-protein is associated with Id-1 overexpression in the majority of invasive breast cancer tissues ($P < 0.0001$). In contrast, this coexpression is limited to 8 cases out of 26 in *in situ* breast cancer ($P < 0.0001$). Furthermore, the expression levels of Id-1 in these tissues vary from weak to moderate.




Figure 1 Association between the presence of HPV type 33 and Id-1 overexpression in human invasive breast cancer in a sample patient. We noted that E6 expression of HPV type 33 is correlated with Id-1 overexpression in invasive breast cancer using tissue microarray analysis. Magnification is $\times 200$. The presence of HPV type 33 was confirmed by PCR using specific primers for the E6 gene of this virus.

ACKNOWLEDGEMENTS

We are grateful to Drs G Batist and W Foulkes for their support of this work. We are thankful to Dr TA Bismar and Ms M Crosato for

their critical discussion and reading of the paper. We also thank Dr R Shammaa and R Ricciardi for their technical assistance. This work is supported by the Canadian Institutes for Health Research and the Fonds de la Recherche en Santé du Québec (FRSQ- Réseau du Cancer).

REFERENCES

- Al Moustafa AE, Foulkes WD, Benlimame N, Wong A, Yen L, Bergeron J, Batist G, Alpert L, Alaoui-Jamali MA (2004) E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells. *Oncogene* **23**: 350–358
- Begum S, Gillison ML, Ansari-Lari MA, Shah K, Westra WH (2003) Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. *Clin Cancer Res* **9**: 6469–6475
- Damin AP, Karam R, Zettler CG, Caleffi M, Alexandre CO (2004) Evidence for an association of human papillomavirus and breast carcinomas. *Breast Cancer Res Treat* **84**: 131–137
- Damin DC, Caetano MB, Rosito MA, Schwartzmann G, Damin AS, Frazzon AP, Ruppenthal RD, Alexandre CO (2007) Evidence for an association of human papillomavirus infection and colorectal cancer. *Eur J Surg Oncol* **33**: 569–574
- de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX (2007) Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. *Lancet Infect Dis* **7**: 453–459
- de Villiers EM, Sandstrom RE, zur Hausen H, Buck CE (2005) Presence of papillomavirus sequences in condylomatous lesions of the mamillae and in invasive carcinoma of the breast. *Breast Cancer Res* **1**: R1–R11
- Desprez PY, Lin CQ, Thomasset N, Simpson CJ, Bissell MJ, Campisi J (1998) A novel pathway for mammary epithelial cell invasion induced by the helix-loop-helix protein Id-1. *Mol Cell Biol* **18**: 4577–4588
- Dyson N, Guida P, Munger K, Harlow E (1992) Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. *J Virol* **66**: 6893–6902
- Dyson N, Howley PM, Munger K, Harlow E (1989) The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. *Science* **243**: 934–937
- Fong S, Debs RJ, Desprez PY (2004) Id genes proteins as promising targets in cancer therapy. *Trends Mol Med* **10**: 387–392
- Fong S, Itahana Y, Sumida T, Singh J, Coppe JP, Liu Y, Richards PC, Bennington JL, Lee NM, Debs RJ, Desprez PY (2003) Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis. *Proc Natl Acad Sci USA* **100**: 13543–13548
- Gopalkrishna V, Singh UR, Sodhani P, Sharma JK, Hedau ST, Mandal AK, Das BC (1996) Absence of human papillomavirus DNA in breast cancer as revealed by polymerase chain reaction. *Breast Cancer Res Treat* **39**: 197–202
- Graflund M, Sorbe B, Sigurdardottir S, Karlsson M (2004) HPV-DNA, vascular space invasion, and their impact on the clinical outcome in early-stage cervical carcinomas. *Int J Gynecol Cancer* **14**: 896–902
- Gumus M, Yumuk PF, Salepci T, Aliustaoglu M, Dane F, Ekenel M, Basaran G, Kaya H, Barisik N, Turhal NS (2006) HPV DNA frequency and subset analysis in human breast cancer patients' normal and tumoral tissue samples. *J Exp Clin Cancer Res* **25**: 515–521
- Hennig EM, Suo Z, Thoresen S, Holm R, Kvinnsland S, Nesland JM (1999) Human papillomavirus 16 in breast cancer of women treated for high-grade cervical intraepithelial neoplasia (CIN III). *Breast Cancer Res Treat* **53**: 121–135
- Jang KS, Han HX, Paik SS, Brown PH, Kong G (2006) Id-1 overexpression in invasive ductal carcinoma cells is significantly associated with intratumoral microvessel density in ER-negative/node-positive breast cancer. *Cancer Lett* **244**: 203–210
- Kan CY, Iacopetta BJ, Lawson JS, Whitaker NJ (2005) Identification of human papillomavirus DNA gene sequences in human breast cancer. *Br J Cancer* **93**: 946–948
- Kroupis C, Markou A, Vourlidis N, Dionysiou-Asteriou A, Lianidou ES (2006) Presence of high-risk human papillomavirus sequences in breast cancer tissues and association with histopathological characteristics. *Clin Biochem* **39**: 727–731
- Kuefer R, Hofer MD, Gschwend JE, Rubin MA (2004) Tissue microarrays. High-throughput procedures to verify potential biomarkers. *Urologe A* **43**: 659–667
- Lin CQ, Singh J, Murata K, Itahana Y, Parrinello S, Liang SH, Gillett CE, Campisi J, Desprez PY (2000) A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells. *Cancer Res* **60**: 1332–1340
- Lindel K, Forster A, Altermatt HJ, Greiner R, Gruber G (2007) Breast cancer and human papillomavirus (HPV) infection: no evidence of a viral etiology in a group of Swiss women. *Breast* **16**: 172–177
- Liu Y, Klimberg VS, Andrews NR, Hicks CR, Peng H, Chiriva-Internati M, Henry-Tillman R, Hermonat PL (2001) Human papillomavirus DNA is present in a subset of unselected breast cancers. *J Hum Virol* **4**: 329–334
- Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J (2005) Genes that mediate breast cancer metastasis to lung. *Nature* **436**: 518–524
- Ouyang XS, Wang X, Lee DT, Tsao SW, Wong YC (2002) Over expression of Id-1 in prostate cancer. *J Urol* **167**: 2598–2602
- Scheffner M, Huibregtse JM, Vierstra RD, Howley PM (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitin–protein ligase in the ubiquitination of p53. *Cell* **75**: 495–505
- Schindl M, Oberhuber G, Obermair A, Schoppmann SF, Karner B, Birner P (2001) Overexpression of Id-1 protein is a marker for unfavorable prognosis in early-stage cervical cancer. *Cancer Res* **61**: 5703–5706
- Schoppmann SF, Schindl M, Bayer G, Aumayr K, Dienes J, Horvat R, Rudas M, Gnant M, Jakesz R, Birner P (2003) Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer. *Int J Cancer* **104**: 677–682
- Sikder HA, Devlin MK, Dunlap S, Ryu B, Alani RM (2003) Id proteins in cell growth and tumorigenesis. *Cancer Cell* **3**: 525–530
- Sturgis EM, Cinciripini PM (2007) Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? *Cancer* **110**: 1429–1435
- Tsai JH, Tsai CH, Cheng MH, Lin SJ, Xu FL, Yang CC (2005) Association of viral factors with non-familial breast cancer in Taiwan by comparison with non-cancerous, fibroadenoma, and thyroid tumor tissues. *J Med Virol* **75**: 276–281
- Umudum H, Rezanko T, Dag F, Dogruluk T (2005) Human papillomavirus genome detection by *in situ* hybridization in fine-needle aspirates of metastatic lesions from head and neck squamous cell carcinomas. *Cancer* **105**: 71–77
- Varnai AD, Bollmann M, Griefingholt H, Speich N, Schmitt C, Bollmann R, Decker D (2006) HPV in anal squamous cell carcinoma and anal intraepithelial neoplasia (AIN). Impact of HPV analysis of anal lesions on diagnosis and prognosis. *Int J Colorectal Dis* **21**: 135–142
- Vousden KH (1995) Regulation of the cell cycle by viral oncoproteins. *Semin Cancer Biol* **6**: 109–116
- Yasmeen A, Bismar TA, Kandouz M, Foulkes WD, Desprez PY, Al Moustafa AE (2007a) E6/E7 of HPV type 16 promotes cell invasion and metastasis of human breast cancer cells. *Cell Cycle* **6**: 2038–2042
- Yasmeen A, Ricciardi R, Kassab A, Bismar TA, Al Moustafa AE (2007b) High-risk HPVs in human breast cancer and normal mammary tissues. *Breast* **16**: 445
- Yu Y, Morimoto T, Sasa M, Okazaki K, Harada Y, Fujiwara T, Irie Y, Takahashi E, Tanigami A, Izumi K (2000) Human papillomavirus type 33 DNA in breast cancer in Chinese. *Breast Cancer* **7**: 33–36
- Yu Y, Morimoto T, Sasa M, Okazaki K, Harada Y, Fujiwara T, Irie Y, Takahashi E, Tanigami A, Izumi K (1999) HPV33 DNA in premalignant and malignant breast lesions in Chinese and Japanese populations. *Anticancer Res* **19**: 5057–5061
- Zuna RE, Allen RA, Moore WE, Mattu R, Dunn ST (2004) Comparison of human papillomavirus genotypes in high-grade squamous intraepithelial lesions and invasive cervical carcinoma: evidence for differences in biologic potential of precursor lesions. *Mod Pathol* **17**: 1314–1322